1373522-70-3

Upstream product

• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 110-91-8 morpholine 
• 401-78-5 3-bromo-1-trifluoromethylbenzene 

Downstream Products

• 1373522-26-9 4-(2-ethyl-3-(5-(4-morpholino-3-(trifluoromethyl)phenyl)-1,2,4-thiadiazol-3-yl)phenyl)butanoic acid 
• 1373522-71-4 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenyl)morpholine 
• 1373522-72-5 4-(4-(3-bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)phenyl)morpholine 

Relevant academic research and scientific papers

Bicyclic alkaloid compound, preparation method and applications thereof

The present invention relates to a bicyclic alkaloid compound, or a tautomer, a stereoisomer, a racemate, the non-equal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition containing the compound. The invention further discloses uses of the compounds and the pharmaceutical composition thereof as drugs, especially as anti-inflammatory drugs and anti-fibrotic drugs.

HETEROARYL SYK INHIBITORS

The invention relates to new substituted heteroarylsof formula (1) wherein A is selected from the group consisting of N and CH, D is selected from the group consisting of S and O, E is C, T is C, G is C, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.